Zacks Highlights Five Biotech Stocks Poised for Q2 Earnings Beats

Analyst
โดย Zacks Investment Research·Read original
Summary · why it matters

Zacks Equity Research has identified five biotech companies that are expected to beat earnings estimates in their upcoming second-quarter 2026 reports. The stocks are Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed, and Agios Pharmaceuticals, each combining a positive Earnings ESP with a Zacks Rank of 1, 2, or 3. Harmony Biosciences carries an Earnings ESP of +14.14% and a Zacks Rank #1, with a consensus estimate of 97 cents per share, and reports on August 4 before the open. Acadia Pharmaceuticals has an Earnings ESP of +25.00% and a Zacks Rank #2, with a consensus of 6 cents per share, reporting after the close on August 4. Biogen shows an Earnings ESP of +220.79% and a Zacks Rank #3, with a consensus of 94 cents per share, and reports on July 29 before the open. Insmed has an Earnings ESP of +22.32% and a Zacks Rank #3, with a consensus loss of 69 cents per share, reporting on August 6 before the open. Agios Pharmaceuticals has an Earnings ESP of +12.67% and a Zacks Rank #3, with a consensus loss of $1.86 per share, and reports on July 30 before the open.

Impact on stocks 6

Biotech & Genomic Medicine▲ · 6 stocks
ACADIA Pharmaceuticals Inc
ACAD
▲ PositiveCapitalrelevance

Zacks identifies Acadia as likely to beat Q2 earnings estimates with a positive Earnings ESP and Zacks Rank #2.

Agios Pharm
AGIO
▲ PositiveCapitalrelevance

Zacks identifies Agios as likely to beat Q2 earnings estimates with a positive Earnings ESP and Zacks Rank #3.

Biogen Inc
BIIB
▲ PositiveCapitalrelevance

Zacks identifies Biogen as likely to beat Q2 earnings estimates with a positive Earnings ESP and Zacks Rank #3.

Harmony Biosciences Holdings
HRMY
▲ PositiveCapitalrelevance

Zacks identifies Harmony Biosciences as likely to beat Q2 earnings estimates with a positive Earnings ESP and Zacks Rank #1.

Insmed Inc
INSM
▲ PositiveCapitalrelevance

Zacks identifies Insmed as likely to beat Q2 earnings estimates with a positive Earnings ESP and Zacks Rank #3.

© 2026 MarketDXNews